4.6 Article

Gadolinium-Bisphosphonate Nanoparticle-Based Low-Dose Radioimmunotherapy for Osteosarcoma

Journal

ACS BIOMATERIALS SCIENCE & ENGINEERING
Volume 8, Issue 12, Pages 5329-5337

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsbiomaterials.2c00880

Keywords

radioimmunotherapy; osteosarcoma; radiosensitizer; nanoparticles; theranostic nanoparticles

Funding

  1. National Natural Science Foundation of China [31771104, 32171403, 31971319, 12075164, 21874097]
  2. National Key Research Program of China [2018YFA0208800]
  3. Suzhou Administration of Science and Technology [sys2018021]
  4. Scientific Research Program for Young Talents of China National Nuclear Corporation
  5. Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)

Ask authors/readers for more resources

In this study, therapeutic gadolinium-based metalbisphosphonate nanoparticles (NPs) were synthesized for osteosarcoma treatment to enhance radiotherapy effects and activate the immune system, showing a strong antitumor effect.
Osteosarcoma is a malignant osteogenic tumor with a high metastatic rate commonly occurring in adolescents. Although radiotherapy is applied to treat unresectable osteosarcoma with radiation resistance, a high dose of radiotherapy is required, which may weaken the immune microenvironment. Therefore, there is an urgent need to develop novel agents to maximize the radiotherapeutic effects by eliciting immune activation effects. In this study, we synthesized therapeutic gadolinium-based metalbisphosphonate nanoparticles (NPs) for osteosarcoma treatment that can be combined with radiotherapy. The gadolinium ion (Gd) was chelated with zoledronic acid (Zol), a commonly used drug to prevent/treat osteoporosis or bone metastases from advanced cancers, and stabilized by ovalbumin (OVA) to produce OVA-GdZol NPs. OVA-GdZol NPs were internalized into K7M2 osteosarcoma cells, showing a high sensitization effect under X-ray irradiation. Cell pretreatment of OVA-GdZol NPs significantly enhanced the radiation therapeutic effect in vitro by reducing the cell colonies and increased the signal of gamma H2AX-positive cells. More importantly, OVA-GdZol NPs promoted the maturation of bone marrow-derived dendritic cells (BMDCs) and M1 polarization of macrophages. The inhibitory effect on K7M2 osteosarcoma of OVA-GdZol NPs and X-ray radiation was evident, indicated by a significantly reduced tumor volume, high survival rate, and decreased lung metastasis. Meanwhile, both innate and adaptive immune systems were activated to exert a strong antitumor effect. The above results highly suggest that OVA-GdZol NPs serve as both radiosensitizers and immune adjuvants, suitable for the sequential combination of vaccination and radiotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available